Analysts Issue Forecasts for BCYC FY2026 Earnings

Bicycle Therapeutics plc (NASDAQ:BCYC) – Analysts at Leerink Partnrs issued their FY2026 EPS estimates for shares of Bicycle Therapeutics in a research report issued on Tuesday, February 25th. Leerink Partnrs analyst J. Chang expects that the company will post earnings of ($3.67) per share for the year. The consensus estimate for Bicycle Therapeutics’ current full-year earnings is ($3.06) per share.

Several other research analysts also recently weighed in on BCYC. JMP Securities lowered their target price on Bicycle Therapeutics from $32.00 to $26.00 and set a “market outperform” rating on the stock in a research note on Wednesday, December 18th. B. Riley lowered their price objective on shares of Bicycle Therapeutics from $28.00 to $17.00 and set a “neutral” rating on the stock in a research report on Friday, December 13th. Stephens reissued an “equal weight” rating and issued a $15.00 price objective on shares of Bicycle Therapeutics in a research note on Wednesday, January 22nd. Needham & Company LLC restated a “buy” rating and issued a $30.00 target price on shares of Bicycle Therapeutics in a research note on Wednesday. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $35.00 target price on shares of Bicycle Therapeutics in a report on Friday, November 1st. Two analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $29.14.

Bicycle Therapeutics Stock Down 0.5 %

NASDAQ BCYC opened at $10.97 on Thursday. The business’s 50-day moving average price is $13.27 and its 200 day moving average price is $19.40. The firm has a market cap of $757.43 million, a P/E ratio of -3.33 and a beta of 0.93. Bicycle Therapeutics has a 52-week low of $10.81 and a 52-week high of $28.67.

Bicycle Therapeutics (NASDAQ:BCYC) last issued its quarterly earnings data on Tuesday, February 25th. The company reported ($0.75) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.85) by $0.10. The company had revenue of $3.70 million for the quarter, compared to the consensus estimate of $5.47 million. Bicycle Therapeutics had a negative net margin of 450.64% and a negative return on equity of 27.35%. Bicycle Therapeutics’s revenue for the quarter was down 30.2% on a year-over-year basis. During the same period last year, the firm posted ($1.16) EPS.

Institutional Investors Weigh In On Bicycle Therapeutics

Large investors have recently added to or reduced their stakes in the business. Assetmark Inc. purchased a new stake in shares of Bicycle Therapeutics in the third quarter valued at about $34,000. Barclays PLC raised its position in shares of Bicycle Therapeutics by 878.3% during the 4th quarter. Barclays PLC now owns 2,612 shares of the company’s stock worth $37,000 after purchasing an additional 2,345 shares during the last quarter. Avior Wealth Management LLC purchased a new stake in Bicycle Therapeutics in the 4th quarter valued at approximately $57,000. China Universal Asset Management Co. Ltd. grew its holdings in Bicycle Therapeutics by 69.1% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 7,138 shares of the company’s stock valued at $162,000 after buying an additional 2,918 shares during the last quarter. Finally, JPMorgan Chase & Co. increased its position in Bicycle Therapeutics by 26.8% during the third quarter. JPMorgan Chase & Co. now owns 8,424 shares of the company’s stock worth $191,000 after buying an additional 1,782 shares in the last quarter. 86.15% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Bicycle Therapeutics

In other news, Director Bros. Advisors Lp Baker acquired 985,397 shares of Bicycle Therapeutics stock in a transaction that occurred on Friday, December 13th. The stock was purchased at an average cost of $13.76 per share, with a total value of $13,559,062.72. Following the completion of the acquisition, the director now owns 9,537,643 shares in the company, valued at $131,237,967.68. This trade represents a 11.52 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CAO Travis Alvin Thompson sold 2,686 shares of the company’s stock in a transaction on Monday, January 6th. The shares were sold at an average price of $15.00, for a total value of $40,290.00. Following the completion of the sale, the chief accounting officer now directly owns 32,146 shares in the company, valued at $482,190. This trade represents a 7.71 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 27,677 shares of company stock valued at $392,413 in the last ninety days. 8.50% of the stock is currently owned by company insiders.

About Bicycle Therapeutics

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.